Int J Med Sci 2022; 19(7):1103-1109. doi:10.7150/ijms.73417 This issue

Research Paper

The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a population-based cohort study

Hsiang-Wen Chien1,2,3,4, Chiao-Wen Lin5,6, Chia-Yi Lee7, Jing-Yang Huang8,9, Shun-Fa Yang8,9✉, Kai Wang1,2,3✉

1. Department of Ophthalmology, Cathay General Hospital, Taipei, Taiwan.
2. Departments of Ophthalmology, Sijhih Cathay General Hospital, New Taipei City, Taiwan.
3. School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan.
4. School of Medicine, National Tsing Hua University, Hsinchu, Taiwan, Taiwan.
5. Institute of Oral Sciences, Chung Shan Medical University, Taichung, Taiwan.
6. Department of Dentistry, Chung Shan Medical University Hospital, Taichung, Taiwan.
7. Department of Ophthalmology, Nobel Eye Institute, Taipei, Taiwan.
8. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
9. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Chien HW, Lin CW, Lee CY, Huang JY, Yang SF, Wang K. The use of androgen deprivation therapy for prostate cancer and its effect on the subsequent dry eye disease: a population-based cohort study. Int J Med Sci 2022; 19(7):1103-1109. doi:10.7150/ijms.73417. Available from https://www.medsci.org/v19p1103.htm

File import instruction

Abstract

Graphic abstract

This study aimed to investigate the influence of androgen deprivation therapy (ADT) for the development of dry eye disease (DED) in subjects with prostate cancer via the use of national health insurance research database (NHIRD) of Taiwan. A retrospective cohort study was conducted and patients were selected as prostate cancer with ADT according to diagnostic and procedure codes. Each participant in that group was then matched to one patient with prostate cancer but without ADT and two subject s without prostate cancer and ADT. And a total of 1791, 1791 and 3582 participants were enrolled in each group. The primary outcome was set as the DED development according to the diagnostic codes. Cox proportional hazard regression was applied to calculate the adjusted hazard ratio (aHR) and 95% confidence interval (CI) of ADT and other parameters for DED development. There were 228, 126 and 95 new events of DED developed in the control group, the prostate cancer without ADT group and the prostate cancer with ADT group. The rate of DED in the prostate cancer with ADT group (aHR: 0.980, 95% CI: 0.771-1.246, P= 0.8696) and Prostate cancer without ADT group (aHR: 1.064, 95% CI: 0.855-1.325, P= 0.5766) were not significantly different compared to the control group. In addition, the patients aged 70-79 years old demonstrated a significantly higher incidence of developing DED compared to those aged 50-59 years old (aHR: 1.885, 95% CI: 1.188-2.989, P= 0.0071). In conclusion, the use of ADT did not alter the incidence of subsequent DED.

Keywords: androgen deprivation therapy, dry eye disease, age, database, epidemiology